Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Zania Stamataki, Associate Professor in Viral Immunology, University of Birmingham

The WHO has advised against the use of two antibody therapies against COVID – here's what that means

Sotrovimab and casirivimab-imdevimab are no longer recommended for patients with COVID. ice_blue/Shutterstock

New guidance from the World Health Organization (WHO) strongly advises against using the antibody therapies sotrovimab and casirivimab-imdevimab to treat patients with COVID-19.

This guidance, published in the British Medical Journal, replaces previous conditional recommendations for the use of these drugs. It’s based on emerging evidence that they’re not likely to work against current COVID variants such as omicron.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.